These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 20563583

  • 1. Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis.
    Oguri T, Shimokata T, Inada M, Ito I, Ando Y, Sasaki Y, Hasegawa Y.
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):813-7. PubMed ID: 20563583
    [Abstract] [Full Text] [Related]

  • 2. Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer.
    Watanabe M, Aoki Y, Tomita M, Sato T, Takaki Y, Kato N, Kikuchi M, Kase H, Tanaka K.
    Gynecol Oncol; 2002 Feb; 84(2):335-8. PubMed ID: 11812097
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of carboplatin in a hemodialysis patient with small-cell lung cancer.
    Hiraike M, Hiraki Y, Misumi N, Hanada K, Tsuji Y, Kamimura H, Karube Y, Kashiwabara K.
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):845-8. PubMed ID: 22194156
    [Abstract] [Full Text] [Related]

  • 4. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
    Okamoto H, Nagatomo A, Kunitoh H, Kunikane H, Watanabe K.
    Cancer Chemother Pharmacol; 1998 Mar; 42(4):307-12. PubMed ID: 9744776
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
    Warren K, Gervais A, Aikin A, Egorin M, Balis FM.
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
    [Abstract] [Full Text] [Related]

  • 6. Carboplatin-based chemotherapy in patients undergoing hemodialysis.
    Yanagawa H, Takishita Y, Bando H, Sumitani H, Okada S.
    Anticancer Res; 1996 Sep; 16(1):533-5. PubMed ID: 8615666
    [Abstract] [Full Text] [Related]

  • 7. [Pharmacokinetics of paclitaxel and carboplatin in a hemodialysis patient with metastatic urothelial carcinoma--a case report].
    Furuya Y, Takihana Y, Araki I, Tanabe N, Takeda M.
    Gan To Kagaku Ryoho; 2003 Jul; 30(7):1017-20. PubMed ID: 12894722
    [Abstract] [Full Text] [Related]

  • 8. Effect of age on systemic exposure and haematological toxicity of carboplatin in advanced non-small cell lung cancer patients.
    Merino-Sanjuán M, Monteiro JF, Porta-Oltra B, Maestu I, Almenar D, Jiménez-Torres NV.
    Basic Clin Pharmacol Toxicol; 2011 Dec; 109(6):457-64. PubMed ID: 21726412
    [Abstract] [Full Text] [Related]

  • 9. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
    Glorieux P, Ortmanns P, Marien S, Degives R, Degraeve D, Potvin M, Grauwels D, Schallier D.
    Anticancer Res; 2001 Dec; 21(2B):1487-94. PubMed ID: 11396237
    [Abstract] [Full Text] [Related]

  • 10. Flat dosing of carboplatin is justified in adult patients with normal renal function.
    Ekhart C, de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH.
    Clin Cancer Res; 2006 Nov 01; 12(21):6502-8. PubMed ID: 17085665
    [Abstract] [Full Text] [Related]

  • 11. Extension of the Calvert formula to patients with severe renal insufficiency.
    Oguri T, Shimokata T, Ito I, Yasuda Y, Sassa N, Nishiyama M, Hamada A, Hasegawa Y, Ando Y.
    Cancer Chemother Pharmacol; 2015 Jul 01; 76(1):53-9. PubMed ID: 25957958
    [Abstract] [Full Text] [Related]

  • 12. [Safe and effective administration of carboplatin-based chemotherapy in a patient undergoing hemodialysis with cancer of unknown primary by monitoring observed AUC of carboplatin-a case report].
    Kondo M, Kuroda J, Ikai Y, Hayashi R, Uegaki S, Yoshida T, Yoshida A, Komatsu H, Kimura K.
    Gan To Kagaku Ryoho; 2012 Nov 01; 39(11):1749-52. PubMed ID: 23152033
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma.
    Niioka T, Uno T, Yasui-Furukori N, Takahata T, Shimizu M, Sugawara K, Tateishi T.
    Cancer Chemother Pharmacol; 2007 Apr 01; 59(5):575-80. PubMed ID: 16912889
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin.
    Holweger K, Lipp HP, Beijnen JH, Bokemeyer C, Hartmann JT.
    Cancer Chemother Pharmacol; 2011 Sep 01; 68(3):693-701. PubMed ID: 21136060
    [Abstract] [Full Text] [Related]

  • 15. Dose-banding of carboplatin: rationale and proposed banding scheme.
    Kaestner S, Sewell G.
    J Oncol Pharm Pract; 2007 Jun 01; 13(2):109-17. PubMed ID: 17873111
    [Abstract] [Full Text] [Related]

  • 16. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
    Porter D, Boddy A, Thomas H, Lind M, Newell D, Calvert AH, Robson L, Brampton M, Abrahamsen D, Winograd B.
    Semin Oncol; 1996 Dec 01; 23(6 Suppl 13):34-44. PubMed ID: 8996574
    [Abstract] [Full Text] [Related]

  • 17. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
    Langer CJ, Millenson M, Rosvold E, Litwin S, McAleer CA, Bonjo CA, Ozols R.
    Semin Oncol; 1997 Aug 01; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
    [Abstract] [Full Text] [Related]

  • 18. Clinical pharmacology of carboplatin administered in combination with paclitaxel.
    van Warmerdam LJ, Huizing MT, Giaccone G, Postmus PE, ten Bokkel Huinink WW, van Zandwijk N, Koolen MG, Helmerhorst TJ, van der Vijgh WJ, Veenhof CH, Beijnen JH.
    Semin Oncol; 1997 Feb 01; 24(1 Suppl 2):S2-97-S2-104. PubMed ID: 9045347
    [Abstract] [Full Text] [Related]

  • 19. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai Gynecology Study Group (SGSG) study.
    Miyagi Y, Fujiwara K, Kigawa J, Itamochi H, Nagao S, Aotani E, Terakawa N, Kohno I, Sankai Gynecology Study Group (SGSG).
    Gynecol Oncol; 2005 Dec 01; 99(3):591-6. PubMed ID: 16095677
    [Abstract] [Full Text] [Related]

  • 20. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
    Yamamoto R, Kaneuchi M, Nishiya M, Todo Y, Takeda M, Okamoto K, Negishi H, Sakuragi N, Fujimoto S, Hirano T.
    Cancer Chemother Pharmacol; 2002 Aug 01; 50(2):137-42. PubMed ID: 12172979
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.